ASweetLife Team
ASweetLife Team

Biodel logo

Biodel Initiates a Phase 2 Study of Ultra-Rapid-Acting Insulin

Biodel has initiated a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting mealtime insulin candidate, BIOD-123. The study is designed to assess the clinical impact of the ultra-rapid absorption profile of BIOD-123 relative to currently marketed mealtime insulin analogs. In April 2012, Biodel announced positive top-line results from a Phase 1 clinical trial of BIOD-123, which demonstrated that the formulation had a more rapid absorption...
0 Shares
SAM TALBOT

OneTouch Launches Sweepstakes to Promote Healthy Eating

Celebrity chef Sam Talbot has partnered with the glucose monitors maker OneTouch to launch the What’s Cookin’ Down Home Healthy™ Sweepstakes. The sweepstakes, designed to spread the word that eating healthy with diabetes can also be easy and delicious, will run for five weeks, beginning September 11th and is open to individuals 18 or older by visiting the OneTouch Facebook page.
0 Shares
diabetesmine_logo_small

Have Type 2 Diabetes? Take This Survey

Amy Tenderich of Diabetes Mine is compiling data for an article in the ADA journal Diabetes Spectrum.  The article will discuss feedback from…
0 Shares

Lilly Diabetes Launches Glucagon Mobile App

Lilly Diabetes today announced the release of a new mobile application designed for caregivers and healthcare providers who support people with type 1 diabetes. The Lilly Glucagon Mobile App is a tool to teach how to use Glucagon for injection, through simulated practice. Glucagon, 1 mg (1 unit), is indicated to treat severe hypoglycemia (low blood sugar). Severe hypoglycemia due to insulin may result in loss of consciousness (insulin coma).
0 Shares

FDA Approves Janssen’s NUCYNTA ER for Diabetic Peripheral Neuropathy Pain

The U.S. FDA has approved the supplemental New Drug Application (sNDA), submitted by Janssen Pharmaceuticals, for NUCYNTA ER (tapentadol) extended-release tablets. NUCYNTA ER is an oral analgesic taken twice daily, for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
0 Shares

Kids First, Diabetes Second

Raising a child with diabetes is anything but easy, and comes with round-the-clock challenges. Leighann Calentine, author of D-Mom Blog has written a book, Kids First, Diabetes Second, which serves as a resource for parents and caregivers of children with diabetes. In the book, Leighann shares her family’s experiences with her daughter’s type 1 diabetes.
0 Shares
Roche-logo

FDA approves Lucentis for Diabetic Macular Edema

The U.S. FDA has approved Roche's Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes. The FDA previously had approved Lucentis to treat wet (neovascular) age-related macular degeneration (AMD), a condition in which abnormal blood vessels grow and leak fluid into the macula. Lucentis also is approved to treat macular edema following retinal vein occlusion...
0 Shares
mass General Hospital logo

Treatment With Generic Vaccine May Temporarily Reverse Type 1 Diabetes

A phase I clinical trial, led by Denise Faustman, MD, PhD, director of the Massachusetts General Hospital (MGH) Immunobiology Laboratory, has confirmed that use of a generic vaccine to raise levels of an immune system modulator can cause the death of autoimmune cells targeting the insulin-secreting cells of the pancreas and temporarily restore insulin secretion in human patients with type 1 diabetes.
0 Shares